Confo Therapeutics

Belgium
Bullange, Wallonia, Belgium, 1050

Company profile

Confo Therapeutics company profile

Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations of these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$1M-$10M
Founded
2015-01-01, Year

Headquarters

Postal code
1050
Country code
BE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
12
Total equity funding
$109.6M
Last funding
Grant / $1.2M / 2025-10-08
Last equity funding
Series B / $65.2M
Investors
17
Lead investors
9
Founders
2
Articles
36

Founders and investors

Founders

Jan SteyaertToon Laeremans

Lead investors

Ackermans & van HaarenAgentschap Innoveren & OndernemenBioGeneration VenturesFlanders Innovation & Entrepreneurship (VLAIO)InnovirisQbic FundThe Institute for the Promotion of Innovation by Science and Technology in FlandersV-Bio VenturesWellington Partners

Investors

BioGeneration VenturesCapricorn PartnersPerceptive AdvisorsV-Bio VenturesWellington Partners